Corvia is proud to support the MUSC Health Charleston HFpEF Conference from July 19-21, 2024. Heart failure with preserved ejection fraction (#HFpEF) is a hot topic — join course director Sheldon Litwin and other esteemed faculty to discover why! #heartfailure #atrialshunt #Interatrialshunt
Corvia Medical, Inc.
Medical Equipment Manufacturing
Tewksbury, MA 2,292 followers
Corvia Medical is revolutionizing the treatment of heart failure (HF) with a novel transcatheter structural heart device
About us
Corvia Medical, Inc. is revolutionizing the treatment of heart failure with a novel transcatheter structural heart device. Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. The Corvia® Atrial Shunt is the world’s first transcatheter device approved by the European Union to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures, Edward Lifesciences and an undisclosed strategic investor. In the United States, the Corvia Atrial Shunt System is an investigational device and not available for commercial distribution or sale.
- Website
-
http://www.corviamedical.com
External link for Corvia Medical, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Tewksbury, MA
- Type
- Privately Held
- Founded
- 2009
- Specialties
- medical device, hfpef, hfref, heart failure, congestive heart failure, interventional cardiology, structural heart, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, and hfmref
Locations
-
Primary
One Highwood Drive
300
Tewksbury, MA 01876, US
Employees at Corvia Medical, Inc.
Updates
-
#CSIFrankfurt2024 begins today! If you are attending the CSI congress don't miss today's session on #atrialshunt therapy at 16:15 CEST. With two #atrialshunt randomized trials now complete, come hear why we believe the #Corvia Atrial Shunt holds promise for #HFpEF and #HFmrEF patients! #heartfailure #interatrialshunt #structuralheart
-
-
#CSIFrankfurt2024 is almost here! Don't miss Wednesday's #Interatrialshunt Focus Workshop where Prof. Amin Polzin from University of Duesseldorf will share lessons learned from REDUCE LAP-HF II and how these findings are being validated in the ongoing #RESPONDERHF confirmatory trial. #atrialshunt #HFpEF #HFmrEF #heartfailure #corvia
-
-
Great story by The Post and Courier featuring a #heartfailure patient Sheldon Litwin treated as part of a clinical trial of the #Corvia #AtrialShunt at Medical University of South Carolina. Jimmy's story gives us confidence we are on the right path with our confirmatory trial #RESPONDERHF. Visit treatmyheartfailure.com to learn more. Caution: The Corvia Atrial Shunt in an investigational device, limited by US law to investigational use. #HFpEF #REDUCELAP https://lnkd.in/eMZD4WkJ
-
Corvia Medical, Inc. reposted this
Over 2 years of follow-up, atrial shunting in patients with HFpEF and HFmrEF led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers but no change in RV systolic function compared with sham. https://ja.ma/3Q61FnM
-
-
What is the long-term effect of an #atrialshunt? Recently published data in JAMA Cardiology shows favorable long-term effects of the Corvia Atrial Shunt on cardiac structure & function in #heartfailure patients with preserved ejection fraction. #HFpEF https://lnkd.in/eBQFfgkt
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction
jamanetwork.com
-
During National Nurses Week, we extend our deepest appreciation to the incredible Heart Failure nurses who play a vital role in the care and management of patients with heart failure. Your collective expertise, empathy, and dedication are instrumental in improving quality of life for millions. Thank you for being the heartbeat of compassionate care. #NursesMakeTheDifference #NationalNursesDay #HeartFailureNursingHeroes #HeartfeltGratitude #NursesWeek2024 #Corvia
-
Happy National Nurses Day to all the dedicated Heart Failure nurses! Your unwavering commitment and compassion make a significant impact on the lives of patients with heart failure. Thank you for your tireless efforts in providing exceptional care and support. Your dedication does not go unnoticed. #NursesMakeTheDifference #NationalNursesDay #HeartFailureNurses #GratefulHeart #NursesWeek2024 #Corvia
-
-
Excellent discussion on the importance of finding the "strike zone" for #atrialshunt therapy in #HFpEF and how several ongoing studies including #RESPONDERHF and #ALLAYHF intend to answer that question.
CEO non-profit Baim / PERFUSE Research Institute, Harvard Professor, Cardiologist BIDMC, Founder & Chairman WikiDoc.org
Should trials of interatrial shunt technologies continue in patients with HpEF? Drs. Jim Udelson and Sanjiv Shah discuss the take home lessons from the RELIEVE HF study and the path forward "We need to find the strike zone, not strike down the device"
-
#Atrialshunt therapy is an emerging field and we continue to learn more about which patients may benefit most. The recently released RELIEVE-HF data reinforces what we learned in REDUCE LAP-HF II - that #heartfailure is heterogeneous and patient selection is critical. We believe we are on the right track with our ongoing #RESPONDERHF trial, which aims to confirm the optimal #HFpEF patients for atrial shunt therapy. https://lnkd.in/eeTGTW7V
Corvia’s RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data - Corvia Medical
https://us.corviamedical.com